Investing.com -- Moderna (NASDAQ:MRNA) has revised its revenue forecast for 2025, causing a decline in the company's share price.
The biotechnology company now expects its 2025 sales to fall between $1.5 billion and $2.5 billion.
This prediction, with a midpoint of $2 billion, falls short of the previous consensus forecast of $2.92 billion.
In response to the revised forecast, Moderna has announced that it will be stepping up its cost-cutting measures.
By the end of 2025, the company aims to have approximately $6 billion in cash. This decision to revise its revenue guidance and increase cost-cutting initiatives has led to a slump in Moderna's shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
MRNA: is this perennial leader facing new challenges?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is MRNA one of them?
Unlock ProPicks AI to find out